Arbor Realty Trust (ABR) 2026 — Quick Summary: ABR is a multifamily-focused mortgage REIT with a $12B bridge loan portfolio and a $36.3B agency servicing book. The dividend was cut from $0.43/Q (2023–Q4 2024) to $0.30/Q (2025) and again to $0.17/Q (Q2 2026). Distributable earnings in Q1 2026 came in at just $0.07/share — the payout exceeds what the company earns. Stock trades at ~$5.42, roughly 48% of book value ($11.30–$11.63). I hold 108 shares at a cost basis of ~€9.71, currently down approximately 52.7%. This analysis explains why I still hold — and what would change my mind. No sugarcoating. Not investment advice.
Published: July 1, 2026 · This article is for informational purposes only and does not constitute investment advice. No buy or sell recommendation. The author holds a position in ABR — conflict of interest disclosed below.
Disclosure (Conflict of Interest): I hold Arbor Realty Trust (ABR) — 108 shares purchased via Scalable Capital / Trade Republic (public brokers). Cost basis: approx. €9.71 per share. Current price: approx. $5.42 (≈ €4.96). Unrealized loss: approx. −52.7%. This analysis is inherently subjective — I have a direct financial interest in ABR recovering. You should know that before reading further.
I will not pretend otherwise writing this: ABR is one of my most painful positions. −52.7% from my cost basis. Two dividend cuts in 18 months. A business model I once considered defensive.
So why write about it? Because I still hold. Not out of stubbornness, but because I understand the thesis — and it has not broken yet. This analysis is an attempt to lay that out clearly.
ABR is not a standard equity REIT that owns and rents properties. It is a mortgage REIT, focused on multifamily (apartment buildings), operating through two core businesses:
ABR provides a bridge loan to an owner of an apartment building that is not yet fully leased. Once the property is stabilized (high occupancy, predictable cash flow), ABR refinances into an agency loan — which is then sold into capital markets. ABR keeps the servicing contract and the recurring fee income. In theory: a self-reinforcing cycle of origination, bridge, agency, servicing, repeat.
The problem in 2024/25: The bridge phase became a bottleneck. Rising rates, flat rents, higher vacancy — many projects could not stabilize. Credit defaults rose. ABR's delinquency rate climbed to approximately 8% of total assets (~$1B in non-performing loans) as of Q1 2026.
Related: Forced Dividend Structures: REITs, BDCs & Why They Must Pay Out
For a mortgage REIT, the dividend is management's statement about earnings capacity. ABR's dividend history over the past two years is clear:
| Period | Dividend/Quarter | Annualized | Status |
|---|---|---|---|
| 2023 – Q4 2024 | $0.43 | $1.72 | Stable |
| Q1 2025 – Q4 2025 | $0.30 | $1.20 | ⬇ −30% cut |
| Q1 2026 (declared) | $0.17 | $0.68 | ⬇ −43% further cut |
Sources: FMP Dividends API (verified), SEC 8-K ABR May 7, 2026. The $0.17 dividend was declared May 7, 2026, record date May 22, payment date June 5, 2026.
Compare: Omega Healthcare (OHI) Analysis 2026 — a REIT with a more stable dividend profile
| Ticker | ABR (NYSE) |
| Sector | Mortgage REIT / Multifamily Lending |
| Stock Price (reference) | approx. $5.42 |
| Book Value/Share (Q1 2026) | approx. $11.30–$11.63 |
| Price/Book | approx. 0.47–0.48× |
| Dividend/Quarter (current) | $0.17 |
| Annualized Dividend | $0.68 |
| Dividend Yield on Price | approx. 12.5% |
| Distributable Earnings Q1 2026 | $0.07/share ($0.18 adjusted) |
| Structured Loan Portfolio | $12.0B |
| Agency Servicing Portfolio | $36.3B |
| Annual Servicing Revenue (prepayment-protected) | approx. $129M |
| Delinquency Rate (Q1 2026) | approx. 8% of assets (~$1B) |
| Total Liabilities | $11.4B (FY2025) |
| Total Equity | $2.95B (FY2025) |
| My Position | 108 shares @ ~€9.71 · −52.7% |
Sources: SEC 8-K ABR Q1 2026, FMP API dividends & balance sheet data FY2025, StockAnalysis.com (book value reference), Globe and Mail (Q1 2026 press release), ABR Investor Presentation March 2026.
No ABR article is complete without this section. In late 2023, Viceroy Research began an aggressive short-seller campaign — "Slumlord Millionaires" (November 2023), followed by multiple follow-up reports through 2024. Core allegations: misrepresentation of loan book quality, inflated book values, questionable underwriting standards.
By summer 2024, parts of these allegations found institutional support: US federal authorities (FBI New York + federal agencies) launched an investigation into the claims. ABR rejected the accusations, pointing to its public disclosures.
Compare: Medical Properties Trust (MPW) Analysis 2026 — another challenged REIT in our portfolio
ABR's bridge loans are largely floating-rate — based on SOFR plus a spread. This means: rising rates technically increase ABR's interest income on paper, but simultaneously squeeze the debt service capacity of borrowers. The longer rates stay elevated, the more borrowers run into trouble.
This negative scissors effect — high nominal interest income, rising credit losses — explains why ABR's distributable earnings collapsed even while the balance sheet showed technically elevated gross yields. Credit risk costs ate the margin.
I still hold ABR. Not because I love it, but because the core thesis has not broken: the agency servicing platform is real, the stock trades at ~48% of book value, and management is actively working through the problem loan book. If by end of 2026 the REO is below $300M and distributable earnings recover toward the dividend level, holding was the right call.
If the federal investigation escalates or delinquencies continue rising: that is my sell trigger. No sentimental attachment — but no panic selling either.
What I would never do: Recommend ABR today as a "safe high-yield REIT with a 13% dividend." The payout is not covered by earnings. The risk is real and measurable.
For ABR, Realty Income, Omega Healthcare, and all REITs — I use InvestingPro for book value trends, earnings history, fair value estimates, and dividend safety scores.
🔥 Get 15% Extra Discount →*Affiliate link. Commission at no extra cost to you.
Not investment advice. All data without warranty. Please conduct your own due diligence. Author holds ABR shares — conflict of interest disclosed.
Related: Realty Income Analysis 2026 · Top 10 High-Yield Dividend Stocks 2026
